Catalent to Acquire Pharmatek

Published on: 

Catalent will acquire Pharmatek, a San Diego-based manufacturer of oral, injectable, and topical products.

On Sept. 13, 2016, Catalent Pharma Solutions announced its plans to acquire Pharmatek Laboratories, a California-based manufacturer of oral, injectable, and topical products. No financial terms of the agreement have been disclosed.

The acquisition of Pharmatek will add spray drying to Catalent’s portfolio of drug formulation and delivery technologies and expand their capability for handling highly potent compounds. Pharmatek offers a drug-development platform including formulation screening, formulation development, analytical services, and finished-dose-form manufacturing for clinical supply. The company also offers solutions for poorly soluble compounds, controlled release formulations, and facilities for potent compound handling.

Pharmatek’s San Diego facility contains two analytical and two formulation laboratories, four engineering rooms, and nine certified ISO Class 8 manufacturing suites. Catalent says they expect the transaction to close within the new few weeks and that the company will pay all cash in the acquisition.


Source: Catalent